300841 康華生物
按盤價 
54.640 +5.930 (+12.174%)
54.640 +5.930 (+12.174%) | 2026/06 - 中期 | 2025/12 | 2024/12 | 2023/12 | 2022/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | 3.948 | 6.296 | 11.453 | 15.455 | 20.817 |
| 總資產報酬率 ROA (%) | 3.537 | 5.472 | 9.680 | 12.858 | 17.776 |
| 投入資產回報率 ROIC (%) | 3.844 | 5.986 | 10.832 | 14.665 | 20.247 | 邊際利潤分析 |
| 銷售毛利率 (%) | 89.765 | 92.035 | 94.203 | 93.453 | 93.562 |
| 營業利潤率 (%) | 29.538 | 22.306 | 32.634 | 36.555 | 47.383 |
| 息稅前利潤/營業總收入 (%) | 29.224 | 21.909 | 32.019 | 35.885 | 46.507 |
| 淨利潤/營業總收入 (%) | 26.219 | 18.875 | 27.841 | 32.282 | 41.339 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | 103.661 | 103.895 | 119.201 | 107.690 | 97.339 |
| 價值變動淨收益/利潤總額(%) | 4.455 | 0.716 | -12.598 | -5.444 | 8.322 |
| 營業外收支淨額/利潤總額(%) | -0.086 | -0.049 | -0.056 | -0.456 | -0.250 | 償債能力分析 |
| 流動比率 (X) | 7.650 | 5.743 | 4.393 | 3.897 | 3.507 |
| 速動比率 (X) | 7.247 | 5.423 | 4.081 | 3.643 | 3.256 |
| 資產負債率 (%) | 8.987 | 11.779 | 14.403 | 16.516 | 17.122 |
| 帶息債務/全部投入資本 (%) | -0.173 | 3.573 | 5.013 | 5.086 | 4.473 |
| 股東權益/帶息債務 (%) | -57,253.090 | 2,674.032 | 1,887.391 | 1,859.192 | 2,130.120 |
| 股東權益/負債合計 (%) | 1,012.731 | 748.965 | 594.323 | 505.461 | 484.054 |
| 利息保障倍數 (X) | -101.195 | -56.689 | -53.596 | -71.230 | -61.344 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 421.070 | 390.035 | 340.596 | 307.828 | 264.297 |
| 存貨周轉天數 (天) | 442.483 | 616.223 | 759.877 | 570.290 | 500.834 |
| 備註： | 報價延遲最少15分鐘，資料更新時間為 18/08/2026 12:27 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
